Applications published 1 August 2007

Published: 7-Jun-2008

Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics
Laboratoires Nuxe 1811953*

Method of reducing nosocomial infections
Zila Pharmaceuticals 1811956*

Solid pharmaceutical compsn comprising donepezil hydrochloride
KRKA 1811957*

Removal of impurities with supercritical fluids from ocular drug delivery devices during manufacturing
Bausch & Lomb 1811958*

Ophthalmic compsn and methods for treating eyes
Allergan 1811959*

Improvements in or relating to pharmaceutical compsns for local administration
novosom 1811960*

Extended surface aggregates in the treatment of skin conditions
Idea 1811961*

Manufacturing process for liposomal preparations
Neopharm 1811962*

Methods of treating cancer with lipid-based platinum compound with lipid-based platinum compound formulations administered intraperitoneally
Transave 1811963*

Granular compsns comprising solidified melt granules of a COX-2 selective inhibitor
Reckit Benckiser Healthcare 1811964*

A process for preparing formulations of lipophilic active substances by spray freeze drying
Solvay Pharmaceuticals 1811965*

Method to produce lung surfactant formulations via lyophilisation and formulations and uses thereof
Discovery Laboratories 1811966*

Methods and formulations for making pharmaceutical compsns containing bupropion
Biokey 1811967*

Dosage forms having a microreliefed surface and methods and apparatus for their production
McNeil-PPC 1811968*

A controlled slow release formulation of thiamine and use thereof in the treatment of pathologies connected to defective process of learning and memorisation
Bioprogress 1811972*

Pharmaceutical compsns comprising (+)-(2S, 3S)-2-(chlorophenyl)-3,5,5-trimethyl-2-morpholinol
SmithKline Beecham 1811973*

Pharmaceutical analysis apparatus and method
SmithKline Beecham 1811974*

Enteric coated compsns that release active ingredient(s) in gastric fluid and intestinal fluid
The State of Oregon acting by and through the State Board of Higher Ed. in behalf of the Oregon State University 1811975*

Immediate release film coating
McNeil-PPC 1811976*

High concentration self-microeulsifying coenzyme Q10 preparations for nutritional use
Bioavailability 1811977*

Production of double- or multi-layered microcapsules
CellMed 1811978*

Microcapsules comprising a methylxanthine and a corticosteroid
Sigmoid Biotechnologies 1811979*

Sealed edible film strip packets and methods of making and using them
Hershey 1811980*

Process for the preparation of suspension aerosols, formulations wherein the particles are formed by precipitation inside an aerosol canister
Generics (UK) 1811981*

Therapeutic treatment of accelerated bone resorption
Can-Fite Biopharma 1811982*

New use for cannabinoid
GW PHarma 1811983*

Compounds which inhibit protein prenylation eg geranylgeranyl-transferase or farnesyltransferase inhibitors for treating Parkinson's disease
Exonhit Therapeutics 1811984*

Nutrient supplement and use of the same
Oy Elmomed 1811985*

Gabapentin prodrug sustained release oral dosage forms
Xenoport 1811986*

Dry powder comprising levothyroxine sodium administered via inhalator
Uni-Pharm Kleon Tsetis Pharmaceutical Laboratories 1811987*

Use of acetyl L-carnitine in combination with propionyl L-carnitine and sildenafil for the treatment of erectile dysfunction
Sigma-Tau Industrie Farmaceutiche Riunite 1811988*

Preparation containing oxidised flavonoid derivatives
Merck Patent 1811989*

Anti-demodicosis agent
Bayer HealthCare 1811990*

Methods of treating diabetes mellitus
Genzyme 1811991*

Methods and compsns using PDE4 modulators for treatment and management of central nervous system injury
Celgene 1811992*

Modulators of CRTH2, COX-2 and FAAH
Microbia 1811993*

Novel derivatives of prophyrin, particularly chlorins and/or bacteriochlorins, and uses thereof in photodynamic therapy
Universidade de Coimbra 1811994*

A transmucosal veterinary compsn comprising detomidine
Orion 1811995*

Compsns for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
Arena Pharmaceuticals 1811996*

Low molecular inhibitors of cytohesin-family guanine nucleotide exchange factors
Rheinische Frederich-Wilhelms-Universitaet Bonn 1811997*

Triazoles useful as inhibitors of protein kinases
Vertex Pharmaceuticals 1811998*

Quinuclidine derivatives and their use as muscarinic M3 receptor antagonists
Novartis 1811999*

Aqueous ophthalmic suspension of crystalline rebamipide
Otsuka Pharmaceutical 1812000*

Nicotinic-opioid synergy for analgesia
The Trustees of Columbia University in the City of New York 1812001*

Treatment of mastitis
Bayer HealthCare 1812002*

Ortho-coated pyridine and pyrimidine derivatives (eg purines) as protein kinases inhibitors
Astex Therapeutics; The Institute of Cancer Research: Royal Cancer Hospital 1812003*

Ortho-condensed pyridine and pyrimidine derivatives (eg purines) as protein kinases inhibitors
Astex Therapeutics; The Institute of Cancer Research: Royal Cancer Hospital 1812004*

Lactam compounds and their use as pharmaceuticals
Incyte 1812005*

Methods of using PDE V inhibitors for the treatment of congestive heart failure
Schering 1812006*

Pyridine compounds and methods
Northwestern University; Universite Louis Pasteur de Strasbourg 1812007*

IL-8 receptor antagonists
SmithKline Beecham 1812008*

GABA-steroid antagonists and their use for the treatment of CNS disorders
Umecrine 1812009*

Use of Na+/K+ APTPase inhibitors and antagonists thereof
BTG International 1812010*

Combined use of vitamin D derivatives and anti-proliferative agents for treating bladder cancer
Bioxell 1812011*

Protein tyrosine phosphatase inhibitors and methods of use thereof
Ceptyr 1812012*

Compsns for treating and/or preventing diseases characterised by the presence of the metal ions
Grenpharma 1812013*

Compsns and methods for prolonging survival of platelets
Zymequest 1812014*

Methods for inhibition of NKT cells
The Board of Trustees of Leland Stanford University 1812015*

Highly branched HK peptides as effective carriers of siRNA
University of Maryland, Baltimore 1812016*

Ophthalmological drugs
Duke University 1812017*

Treatment and prevention of multi-drug resistance
Bayer Schering Pharma Aktiengesellschaft 1812018*

Combination of polychitosamine and HMG-CoA reductase inhibitor for hyperlipidaemia
Magistral Biotech 1812019*

Presbyopia treatment by lens alteration
Newlens 1812020*

One a day formulation for phosphate binders
Genzyme 1812021*

Stand-alone film and methods for making the same
Atrium Medical Corp 1812022*

Trending Articles

You may also like